Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature

Cancer Prevention Research

Volumn 7, Issue 11, 2014, Pages 1081-1107

  Millimouno, Faya M ^a,b,c   Dong, Jia ^a   Yang, Liu ^b   Li, Jiang ^b   Li, Xiaomeng ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c Higher Institute of Science Veterinary Medicine of Dalaba   (Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

CRIPTO 1 PROTEIN; CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NATURAL PRODUCT; NUCLEAR FACTOR; NUCLEAR FACTOR RELATED FACTOR 2; PROTEIN; PROTEIN KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; NFE2L2 PROTEIN, HUMAN; PHENOL DERIVATIVE; PLANT MEDICINAL PRODUCT; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR NRF2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER PREVENTION; CELL CYCLE; CHEMOPROPHYLAXIS; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL FACTOR; TRANSCRIPTION INITIATION; TUMOR CELL; ANIMAL; CHEMISTRY; DRUG DESIGN; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOLOGICAL PRODUCTS; CELL CYCLE; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-E2-RELATED FACTOR 2; NF-KAPPA B; PHENOLS; PHYTOCHEMICALS; SIGNAL TRANSDUCTION;

EID: 84910134369     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0136     Document Type: Review

References (244)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos. CA Cancer J Clin 2012;62:283-98.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010;60:277-300.
4. Wiart C. Goniothalamus species: a source of drugs for the treatment of cancers and bacterial infections? Evid Based Complement Alternat Med 2007;4:299-311.
5. Glade MJ. Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research. Nutrition 1999;15:523-6.
6. Manson MM. Cancer prevention -the potential for diet to modulate molecular signalling. Trends Mol Med 2003;9:11-8.
7. Christen P, Cuendet M. Plants as a source of therapeutic and health products. Chimia (Aarau) 2012;66:320-3.
8. Fulda S. Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol 2010;2010:370835.
9. Hsu CL, Yu YS, Yen GC. Anticancer effects of Alpinia pricei Hayata roots. J Agric Food Chem 2010;58:2201-8.
10. Jaganathan SK, Mandal M. Antiproliferative effects of honey and of its polyphenols: a review. J Biomed Biotechnol 2009;2009:830616.
11. Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009;27:2712-25.
12. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005;100:72-9.
13. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495-516.
14. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005;4:206-20.
15. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-8.
16. Koehn FE, Carter GT. Rediscovering natural products as a source of new drugs. Discov Med 2005;5:159-64.
17. Patwardhan B. Ethnopharmacology and drug discovery. J Ethnopharmacol 2005;100:50-2.
18. Lekphrom R, Kanokmedhakul S, Kanokmedhakul K. Bioactive styryllactones and alkaloid from flowers of Goniothalamus laoticus. J Ethnopharmacol 2009;125:47-50.
19. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
20. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000;102:1-4.
21. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
22. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992;18:1-29.
23. Anichini A, Mortarini R, Sensi M, Zanon M. APAF-1 signaling in human melanoma. Cancer Lett 2006;238:168-79.
24. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
25. Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E. Ethnopharmacology of Mexican asteraceae (Compositae). Annu Rev Pharmacol Toxicol 1998;38:539-65.
26. Kreuger MR, Grootjans S, Biavatti MW, Vandenabeele P, D'Herde K. Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide. Anticancer Drugs 2012;23:883-96.
27. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
28. Budram-Mahadeo V, Morris PJ, Latchman DS. TheBrn-3a transcription factor inhibits the pro-apoptotic effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding Bax and p21(CIP1/Waf1). Oncogene 2002;21:6123-31.
29. Carr AM. Cell cycle. Piecing together the p53 puzzle. Science 2000;287:1765-6.
30. Lu C, El-Deiry WS. Targeting p53 for enhanced radio-and chemosensitivity. Apoptosis 2009;14:597-606.
31. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9.
32. Vogelstein B, Kinzler KW. Achilles' heel of cancer? Nature 2001;412:865-6.
33. Chen S, Cooper M, Jones M, Madhuri TK, Wade J, Bachelor A, et al. Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals. Cell Biol Toxicol 2011;27:133-47.
34. Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol 2005;26:579-88.
35. Chen SS, Michael A, Butler-Manuel SA. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Discov Med 2012;13:7-17.
36. Hahm ER, Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther 2007;6:2686-95.
37. He Z, Subramaniam D, Ramalingam S, Dhar A, Postier RG, Umar S, et al. Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects. Am J Physiol Gastrointest Liver Physiol 2011;301:G929-37.
38. Chilampalli S, Zhang X, Fahmy H, Kaushik RS, Zeman D, Hildreth MB, et al. Chemopreventive effects of honokiol on UVB-induced skin cancer development. Anticancer Res 2010;30:777-83.
39. Fried LE, Arbiser JL. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 2009;11:1139-48.
40. Hahm ER, Arlotti JA, Marynowski SW, Singh SV. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res 2008;14:1248-57.
41. Wang T, Chen F, Chen Z, Wu YF, Xu XL, Zheng S, et al. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol 2004;10:2205-8.
42. Liu E, Kuang Y, He W, Xing X, Gu J. Casticin induces human glioma cell death through apoptosis and mitotic arrest. Cell Physiol Biochem 2013;31:805-14.
43. Zhou Y, Peng Y, Mao QQ, Li X, Chen MW, Su J, et al. Casticin induces caspase-mediated apoptosis via activation of mitochondrial pathway and upregulation of DR5 in human lung cancer cells. Asian Pac J Trop Med 2013;6:372-8.
44. Song YC, Zhang X, Lei GY, Dang CX. [Vitexicarpin affects proliferation and apoptosis in mutated p53 breast cancer cell]. Zhonghua Yi Xue Za Zhi 2010;90:703-7.
45. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427-35.
46. Szoltysek K, Pietranek K, Kalinowska-Herok M, Pietrowska M, Kimmel M, Widlak P. TNFalpha-induced activation of NFkappaB protects against UV-induced apoptosis specifically in p53-proficient cells. Acta Biochim Pol 2008;55:741-8.
47. Gopal YN, Chanchorn E, Van Dyke MW. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther 2009;8:552-62.
48. Di Fiore R, Drago-Ferrante R, D'Anneo A, Augello G, Carlisi D, De Blasio A, et al. In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player. Cancer Biol Ther 2013;14:922-31.
49. Khan M, Li T, Ahmad Khan MK, Rasul A, Nawaz F, Sun M, et al. Alantolactone induces apoptosis in HepG2 cells through GSH depletion, inhibition of STAT3 activation, and mitochondrial dysfunction. Biomed Res Int 2013;2013:719858.
50. Lei JC, Yu JQ, Yin Y, Liu YW, Zou GL. Alantolactone induces activation of apoptosis in human hepatoma cells. Food Chem Toxicol 2012;50:3313-9.
51. Yang C, Yang J, Sun M, Yan J, Meng X, Ma T. Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/Abl and P-glycoprotein expression. IUBMB Life 2013;65:435-44.
52. Rasul A, Khan M, Ali M, Li J, Li X. Targeting apoptosis pathways in cancer with alantolactone and isoalantolactone. ScientificWorldJournal 2013;2013:248532.
53. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203-8.
54. Orlowski RZ, Baldwin AS Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-9.
55. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8:33-40.
56. Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res 2008;42:3-18.
57. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008;8:837-48.
58. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
59. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83.
60. Affara NI, Coussens LM. IKKalpha at the crossroads of inflammation and metastasis. Cell 2007;129:25-6.
61. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115:2625-32.
62. Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006;209:645-52.
63. Tanabe K, Matsushima-Nishiwaki R, Yamaguchi S, Iida H, Dohi S, Kozawa O. Mechanisms of tumor necrosis factor-alpha-induced interleukin-6 synthesis in glioma cells. J Neuroinflammation 2010;7:16.
64. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 2003;278:2903-12.
65. Mathema VB, Koh YS, Thakuri BC, Sillanpaa M. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation 2012;35:560-5.
66. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004;23:7330-44.
67. Yamaguchi M, Arbiser JL, Weitzmann MN. Honokiol stimulates osteoblastogenesis by suppressing NF-kappaB activation. Int J Mol Med 2011;28:1049-53.
68. Zhu X, Wang Z, Hu C, Li Z, Hu J. Honokiol suppresses TNF-alpha-induced migration and matrix metalloproteinase expression by blocking NF-kappaB activation via the ERK signaling pathway in rat aortic smooth muscle cells. Acta Histochem 2014;116:588-95.
69. Butturini E, Di Paola R, Suzuki H, Paterniti I, Ahmad A, Mariotto S, et al. Costunolide and Dehydrocostuslactone, two natural sesquiterpene lactones, ameliorate the inflammatory process associated to experimental pleurisy in mice. Eur J Pharmacol 2014;730C:107-115.
70. Kim JH, Yang YI, Lee KT, Park HJ, Choi JH. Costunolide induces apoptosis in human endometriotic cells through inhibition of the prosurvival Akt and nuclear factor kappa B signaling pathway. Biol Pharm Bull 2011;34:580-5.
71. Whipple RA, Vitolo MI, Boggs AE, Charpentier MS, Thompson K, Martin SS. Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-kappaB inhibition. Breast Cancer Res 2013;15:R83.
72. Karki R, Ho OM, Kim DW. Magnolol attenuates neointima formation by inducing cell cycle arrest via inhibition of ERK1/2 and NF-kappaB activation in vascular smooth muscle cells. Biochim Biophys Acta 2013;1830:2619-28.
73. Li MH, Kothandan G, Cho SJ, Huong PT, Nan YH, Lee KY, et al. Magnolol inhibits LPS-induced NF-kappaB/Rel activation by blocking p38 kinase in murine macrophages. Korean J Physiol Pharmacol 2010;14:353-8.
74. Wang C, Li S, Wang MW. Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol In Vitro 2010;24:898-904.
75. Yang J, Wu LJ, Tashiro S, Onodera S, Ikejima T. Nitric oxide activated by p38 and NF-kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells. Free Radic Res 2008;42:1-11.
76. Zang L, He H, Ye Y, Liu W, Fan S, Tashiro S, et al. Nitric oxide augments oridonin-induced efferocytosis by human histocytic lymphoma U937 cells via autophagy and the NF-kappaB-COX-2-IL-1beta pathway. Free Radic Res 2012;46:1207-19.
77. Chun J, Choi RJ, Khan S, Lee DS, Kim YC, Nam YJ, et al. Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-kappaB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells. Int Immunopharmacol 2012;14:375-83.
78. Wei W, Huang H, Zhao S, Liu W, Liu CX, Chen L, et al. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-kappaB inhibition and Bcr/Abl protein deletion. Apoptosis 2013;18:1060-70.
79. Jia QQ, Wang JC, Long J, Zhao Y, Chen SJ, Zhai JD, et al. Sesquiterpene lactones and their derivatives inhibit high glucose-induced NF-kappaB activation and MCP-1 and TGF-beta1 expression in rat mesangial cells. Molecules 2013;18:13061-77.
80. Koh DJ, Ahn HS, Chung HS, Lee H, Kim Y, Lee JY, et al. Inhibitory effects of casticin on migration of eosinophil and expression of chemokines and adhesion molecules in A549 lung epithelial cells via NF-kappaB inactivation. J Ethnopharmacol 2011;136:399-405.
81. Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L. Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation. J Cell Biochem 2009;108:87-95.
82. Lee SH, Bae EA, Park EK, Shin YW, Baek NI, Han EJ, et al. Inhibitory effect of eupatilin and jaceosidin isolated from Artemisia princeps in IgE-induced hypersensitivity. Int Immunopharmacol 2007;7:1678-84.
83. Karin M. The IkappaB kinase -a bridge between inflammation and cancer. Cell Res 2008;18:334-42.
84. Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, et al. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res 2013;73:4406-17.
85. Yun BR, Lee MJ, Kim JH, Kim IH, Yu GR, Kim DG. Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. Exp Mol Med 2010;42:787-97.
86. Pae HO, Jeong GS, Kim HS, Woo WH, Rhew HY, Kim HS, et al. Costunolide inhibits production of tumor necrosis factor-alpha and interleukin-6 by inducing heme oxygenase-1 in RAW264.7 macrophages. Inflamm Res 2007;56:520-6.
87. Du Y, Villeneuve NF, Wang XJ, Sun Z, Chen W, Li J, et al. Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. Environ Health Perspect 2008;116:1154-61.
88. Seo JY, Park J, Kim HJ, Lee IA, Lim JS, Lim SS, et al. Isoalantolactone from Inula helenium caused Nrf2-mediated induction of detoxifying enzymes. J Med Food 2009;12:1038-45.
89. Seo JY, Lim SS, Kim JR, Lim JS, Ha YR, Lee IA, et al. Nrf2-mediated induction of detoxifying enzymes by alantolactone present in Inula helenium. Phytother Res 2008;22:1500-5.
90. Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999;18:4657-68.
91. Silver DL, Montell DJ. Paracrine signaling through the JAK/STAT pathway activates invasive behavior of ovarian epithelial cells in Drosophila. Cell 2001;107:831-41.
92. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest 1998;102:1385-92.
93. Liu SH, Wang KB, Lan KH, Lee WJ, Pan HC, Wu SM, et al. Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice. PLoS ONE 2012;7:e43711.
94. Chen Z, Sun X, Shen S, Zhang H, Ma X, Liu J, et al. Wedelolactone, a naturally occurring coumestan, enhances interferon-gamma signaling through inhibiting STAT1 protein dephosphorylation. J Biol Chem 2013;288:14417-27.
95. Klippel A, Reinhard C, Kavanaugh WM, Apell G, Escobedo MA, Williams LT. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol Cell Biol 1996;16:4117-27.
96. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8.
97. Han Z, Hong L, Han Y, Wu K, Han S, Shen H, et al. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 2007;26:261-8.
98. Rasul A, Khan M, Yu B, Ali M, Bo YJ, Yang H, et al. Isoalantolactone, a sesquiterpene lactone, induces apoptosis in SGC-7901 cells via mitochondrial and phosphatidylinositol 3-kinase/Akt signaling pathways. Arch Pharm Res 2013;36:1262-9.
99. Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, et al. Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 2007;28:1819-26.
100. Wei WT, Chen H, Wang ZH, Ni ZL, Liu HB, Tong HF, et al. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int J Biol Sci 2012;8:1-14.
101. Dong L, Zhou S, Yang X, Chen Q, He Y, Huang W. Magnolol protects against oxidative stress-mediated neural cell damage by modulating mitochondrial dysfunction and PI3K/Akt signaling. J Mol Neurosci 2013;50:469-81.
102. Rasul A, Yu B, Khan M, Zhang K, Iqbal F, Ma T, et al. Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways. Int J Oncol 2012;40:1153-61.
103. Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT. Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother 2009;32:585-92.
104. Kim BH, Cho JY. Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression. Acta Pharmacol Sin 2008;29:113-22.
105. Shi Y, Bao YL, Wu Y, Yu CL, Huang YX, Sun Y, et al. Alantolactone inhibits cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway. J Biomol Screen 2011;16:525-35.
106. Qiu J, Luo M, Wang J, Dong J, Li H, Leng B, et al. Isoalantolactone protects against Staphylococcus aureus pneumonia. FEMS Microbiol Lett 2011;324:147-55.
107. Schmidt TJ, Brun R, Willuhn G, Khalid SA. Anti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactones. Planta Med 2002;68:750-1.
108. Xin XL, Ma XC, Liu KX, Han J, Wang BR, Guo DA. Microbial transformation of alantolactone by Mucor polymorphosporus. J Asian Nat Prod Res 2008;10:933-7.
109. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 2001;90:157-77.
110. Blagosklonny MV. Aging: ROS or TOR. Cell Cycle 2008;7:3344-54.
111. Lee MG, Lee KT, Chi SG, Park JH. Costunolide induces apoptosis by ROS-mediated mitochondrial permeability transition and cytochrome C release. Biol Pharm Bull 2001;24:303-6.
112. Rasul A, Bao R, Malhi M, Zhao B, Tsuji I, Li J, et al. Induction of apoptosis by costunolide in bladder cancer cells is mediated through ROS generation and mitochondrial dysfunction. Molecules 2013;18:1418-33.
113. Fan S, Li X, Lin J, Chen S, Shan J, Qi G. Honokiol inhibits tumor necrosis factor-alpha-stimulated rat aortic smooth muscle cell proliferation via caspase-and mitochondrial-dependent apoptosis. Inflammation 2014;37:17-26.
114. Wang X, Beitler JJ, Wang H, Lee MJ, Huang W, Koenig L, et al. Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. PLoS ONE 2014;9:e86369.
115. Park JB, Lee MS, Cha EY, Lee JS, Sul JY, Song IS, et al. Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway. Biol Pharm Bull 2012;35:1614-20.
116. Zhou Y, Bi Y, Yang C, Yang J, Jiang Y, Meng F, et al. Magnolol induces apoptosis in MCF-7 human breast cancer cells through G2/M phase arrest and caspase-independent pathway. Pharmazie 2013;68:755-62.
117. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994;344:721-4.
118. Poulsen HE, Prieme H, Loft S. Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev 1998;7:9-16.
119. Coso S, Harrison I, Harrison CB, Vinh A, Sobey CG, Drummond GR, et al. NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts. Antioxid Redox Signal 2012;16:1229-47.
120. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006;11:524-33.
121. Hong IS, Lee HY, Kim HP. Anti-oxidative effects of Rooibos tea (Aspalathus linearis) on immobilization-induced oxidative stress in rat brain. PLoS ONE 2014;9:e87061.
122. Maraldi T. Natural compounds as modulators of NADPH oxidases. Oxid Med Cell Longev 2013;2013:271602.
123. Slater AF, Stefan C, Nobel I, van den Dobbelsteen DJ, Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett 1995;82-83:149-53.
124. Khan M, Ding C, Rasul A, Yi F, Li T, Gao H, et al. Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1 cells. Int J Biol Sci 2012;8:533-47.
125. Khan M, Yi F, Rasul A, Li T, Wang N, Gao H, et al. Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction. IUBMB Life 2012;64:783-94.
126. Pal HC, Sehar I, Bhushan S, Gupta BD, Saxena AK. Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa. Toxicol In Vitro 2010;24:1599-609.
127. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
128. Inoue M, Sato EF, Nishikawa M, Park AM, Kira Y, Imada I, et al. Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr Med Chem 2003;10:2495-505.
129. Chuang DY, Chan MH, Zong Y, Sheng W, He Y, Jiang JH, et al. Magnolia polyphenols attenuate oxidative andinflammatory responses in neurons and microglial cells. J Neuroinflammation 2013;10:15.
130. Han LL, Xie LP, Li LH, Zhang XW, Zhang RQ, Wang HZ. Reactive oxygen species production and Bax/Bcl-2 regulation in honokiol-induced apoptosis in human hepatocellular carcinoma SMMC-7721 cells. Environ Toxicol Pharmacol 2009;28:97-103.
131. Kim MJ, Kim DH, Lee KW, Yoon DY, Surh YJ. Jaceosidin induces apoptosis in ras-transformed human breast epithelial cells through generation of reactive oxygen species. Ann N Y Acad Sci 2007;1095:483-95.
132. Chen D, Cao J, Tian L, Liu F, Sheng X. Induction of apoptosis by casticin in cervical cancer cells through reactive oxygen species-mediated mitochondrial signaling pathways. Oncol Rep 2011;26:1287-94.
133. Zeng F, Tian L, Liu F, Cao J, Quan M, Sheng X. Induction of apoptosis by casticin in cervical cancer cells: reactive oxygen species-dependent sustained activation of Jun N-terminal kinase. Acta Biochim Biophys Sin 2012;44:442-9.
134. Lee CS, Kim YJ, Lee SA, Myung SC, Kim W. Combined effect of Hsp90 inhibitor geldanamycin and parthenolide via reactive oxygen species-mediated apoptotic process on epithelial ovarian cancer cells. Basic Clin Pharmacol Toxicol 2012;111:173-81.
135. Yang YI, Kim JH, Lee KT, Choi JH. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Gynecol Oncol 2011;123:588-96.
136. Rasul A, Di J, Millimouno FM, Malhi M, Tsuji I, Ali M, et al. Reactive oxygen species mediate isoalantolactone-induced apoptosis in human prostate cancer cells. Molecules 2013;18:9382-96.
137. Zhang Y, Bao YL,Wu Y, Yu CL, Huang YX, Sun Y, et al. Alantolactone induces apoptosis in RKO cells through the generation of reactive oxygen species and the mitochondrial pathway. Mol Med Rep 2013;8:967-72.
138. Zang L, He H, Xu Q, Yu Y, Zheng N, Liu W, et al. Reactive oxygen species H2O2 and ∗OH, but not O2∗(-) promote oridonin-induced phagocytosis of apoptotic cells by human histocytic lymphoma U937 cells. Int Immunopharmacol 2013;15:414-23.
139. Zhang YH, Wu YL, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species contribute to oridonin-induced apoptosis and autophagy in human cervical carcinoma HeLa cells. Acta Pharmacol Sin 2011;32:1266-75.
140. Qi M, Fan S, Yao G, Li Z, Zhou H, Tashiro S, et al. Pseudolaric acid B-induced autophagy contributes to senescence via enhancement of ROS generation and mitochondrial dysfunction in murine fibrosarcoma L929 cells. J Pharmacol Sci 2013;121:200-11.
141. Zhao D, Lin F, Wu X, Zhao Q, Zhao B, Lin P, et al. Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells. Toxicol In Vitro 2012;26:595-602.
142. Yang J, Wu LJ, Tashino S, Onodera S, Ikejima T. Critical roles of reactive oxygen species in mitochondrial permeability transition in mediating evodiamine-induced human melanoma A375-S2 cell apoptosis. Free Radic Res 2007;41:1099-108.
143. Yang J, Wu LJ, Tashino S, Onodera S, Ikejima T. Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells. Free Radic Res 2008;42:492-504.
144. Hofmann DK, Fitt WK, Fleck J. Checkpoints in the life-cycle of Cassiopea spp.: control of metagenesis and metamorphosis in a tropical jellyfish. Int J Dev Biol 1996;40:331-8.
145. Sanli T, Steinberg GR, Singh G, Tsakiridis T. AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in theDNAdamage response pathway. Cancer Biol Ther 2014;15:156-69.
146. Tamura RE, de Vasconcellos JF, Sarkar D, Libermann TA, Fisher PB, Zerbini LF. GADD45 proteins: central players in tumorigenesis. Curr Mol Med 2012;12:634-51.
147. Lawen A. Apoptosis-an introduction. Bioessays 2003;25:888-96.
148. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111-21.
149. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 2009;8:2339-47.
150. Curry EA III, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004;22:299-305.
151. Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Exp Hematol 2013;41:799-807 e4.
152. Arora S, Bhardwaj A, Srivastava SK, Singh S, McClellan S, Wang B, et al. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS ONE 2011;6:e21573.
153. Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med 2012;12:1244-52.
154. Chen LC, Lee WS. P27/Kip1 is responsible for magnolol-induced U373 apoptosis in vitro and in vivo. J Agric Food Chem 2013;61:2811-9.
155. Chen MC, Lee CF, Huang WH, Chou TC. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1alpha/VEGF signaling pathway in human bladder cancer cells. Biochem Pharmacol 2013;85:1278-87.
156. Chen XR, Lu R, Dan HX, Liao G, Zhou M, Li XY, et al. Honokiol: a promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells. Int J Oral Sci 2011;3:34-42.
157. Dikalov S, Losik T, Arbiser JL. Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol 2008;76:589-96.
158. Fang F, Gong C, Qian Z, Zhang X, Gou M, You C, et al. Honokiol nanoparticles in thermosensitive hydrogel: therapeutic effects on malignant pleural effusion. ACS Nano 2009;3:4080-8.
159. Hou X, Yuan X, Zhang B, Wang S, Chen Q. Screening active antibreast cancer compounds from Cortex Magnolia officinalis by 2D LCMS. J Sep Sci 2013;36:706-12.
160. Hsu JL, Pan SL, Ho YF, Hwang TL, Kung FL, Guh JH. Costunolide induces apoptosis through nuclear calcium2+ overload and DNA damage response in human prostate cancer. J Urol 2011;185:1967-74.
161. Kang YJ, Park HJ, Chung HJ, Min HY, Park EJ, Lee MA, et al. Wnt/beta-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells. Mol Pharmacol 2012;82:168-77.
162. Ling Y, Zhu J, Fan M, Wu B, Qin L, Huang C. Metabolism studies of casticin in rats using HPLC-ESI-MS(n). Biomed Chromatogr 2012;26:1502-8.
163. Shen JK, Du HP, Yang M, Wang YG, Jin J. Casticin induces leukemic cell death through apoptosis and mitotic catastrophe. Ann Hematol 2009;88:743-52.
164. Yang J, Yang Y, Tian L, Sheng XF, Liu F, Cao JG. Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. World J Gastroenterol 2011;17:4298-307.
165. Ye Q, Zhang QY, Zheng CJ, Wang Y, Qin LP. Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro. Acta Pharmacol Sin 2010;31:1564-8.
166. Jeong JJ, Lee JH, Chang KC, Kim HJ. Honokiol exerts an anticancer effect in T98G human glioblastoma cells through the induction of apoptosis and the regulation of adhesion molecules. Int J Oncol 2012;41:1358-64.
167. Li X, Guo Q, Zheng X, Kong X, Shi S, Chen L, et al. Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery. Drug Deliv 2009;16:160-6.
168. Li Z, Liu Y, Zhao X, Pan X, Yin R, Huang C, et al. Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol 2008;140:95-102.
169. Liang S, Fu A, Zhang Q, Tang M, Zhou J, Wei Y, et al. Honokiol inhibits HepG2 migration via down-regulation of IQGAP1 expression discovered by a quantitative pharmaceutical proteomic analysis. Proteomics 2010;10:1474-83.
170. Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kuhnl A, et al. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol 2008;591:43-51.
171. Liu SH, Shen CC, Yi YC, Tsai JJ, Wang CC, Chueh JT, et al. Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals. Br J Pharmacol 2010;160:1963-72.
172. Mannal PW, Schneider J, Tangada A, McDonald D, McFadden DW. Honokiol produces anti-neoplastic effects on melanoma cells in vitro. J Surg Oncol 2011;104:260-4.
173. Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, et al. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol 2012;227:2184-95.
174. Singh T, Katiyar SK. Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2. Int J Oncol 2011;38:769-76.
175. Tian W, Deng Y, Li L, He H, Sun J, Xu D. Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death. Int J Oncol 2013;42:721-32.
176. Tian W, Xu D, Deng YC. Honokiol, a multifunctional tumor cell death inducer. Pharmazie 2012;67:811-6.
177. Vaid M, Sharma SD, Katiyar SK. Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation. Carcinogenesis 2010;31:2004-11.
178. Wu JP, Zhang W, Wu F, Zhao Y, Cheng LF, Xie JJ, et al. Honokiol: an effective inhibitor of high-glucose-induced upregulation of inflammatory cytokine production in human renal mesangial cells. Inflamm Res 2010;59:1073-9.
179. Ji HY, Kim SY, Kim DK, Jeong JH, Lee HS. Effects of eupatilin and jaceosidin on cytochrome p450 enzyme activities in human liver microsomes. Molecules 2010;15:6466-75.
180. Lee JG, Kim JH, Ahn JH, Lee KT, Baek NI, Choi JH. Jaceosidin, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation. Food Chem Toxicol 2013;55:214-21.
181. Lv W, Sheng X, Chen T, Xu Q, Xie X. Jaceosidin induces apoptosis in human ovary cancer cells through mitochondrial pathway. J Biomed Biotechnol 2008;2008:394802.
182. Choi JH, Lee KT. Costunolide-induced apoptosis in human leukemia cells: involvement of c-jun N-terminal kinase activation. Biol Pharm Bull 2009;32:1803-8.
183. Choi YK, Seo HS, Choi HS, Kim SR, Shin YC, Ko SG. Induction of Fas-mediated extrinsic apoptosis, p21WAF1-related G2/M cell cycle arrest and ROS generation by costunolide in estrogen receptor-negative breast cancer cells, MDA-MB-231. Mol Cell Biochem 2012;363:119-28.
184. Kim SH, Danilenko M, Kim TS. Differential enhancement of leukaemia cell differentiation without elevation of intracellular calcium by plant-derived sesquiterpene lactone compounds. Br J Pharmacol 2008;155:814-25.
185. Kim TJ, Nam KW, Kim B, Lee SJ, Oh KB, Kim KH, et al. Inhibitory effects of costunolide isolated from laurus nobilis on IgE-induced degranulation of mast cell-like RBL-2H3 cells and the growth of Y16 pro-B cells. Phytother Res 2011 Jun 14. [Epub ahead of print].
186. Liu CY, Chang HS, Chen IS, Chen CJ, Hsu ML, Fu SL, et al. Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells. Radiat Oncol 2011;6:56.
187. Cheng G, Xie L. Parthenolide induces apoptosis and cell cycle arrest of human 5637 bladder cancer cells in vitro. Molecules 2011;16:6758-68.
188. Czyz M, Koprowska K, Sztiller-Sikorska M. Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. Cancer Biol Ther 2013;14:135-45.
189. Czyz M, Lesiak-Mieczkowska K, Koprowska K, Szulawska-Mroczek A, Wozniak M. Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br J Pharmacol 2010;160:1144-57.
190. Li Y, Zhang Y, Fu M, Yao Q, Zhuo H, Lu Q, et al. Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma. Mol Med Rep 2012;6:477-82.
191. Liu JW, Cai MX, Xin Y, Wu QS, Ma J, Yang P, et al. Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res 2010;29:108.
192. Nakabayashi H, Shimizu K. Involvement of Akt/NF-kappaB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer 2012;12:453.
193. Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, et al. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species. Int J Cancer 2011;128:2481-94.
194. Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon JH, et al. Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011;8:39-47.
195. Sun Y, St Clair DK, Xu Y, Crooks PA, St Clair WH. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res 2010;70:2880-90.
196. Watson C, Miller DA, Chin-Sinex H, Losch A, Hughes W, Sweeney C, et al. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells. Radiat Res 2009;171:389-96.
197. Wyrebska A, Gach K, Szemraj J, Szewczyk K, Hrabec E, Koszuk J, et al. Comparison of anti-invasive activity of parthenolide and 3-isopropyl-2-methyl-4-methyleneisoxazolidin-5-one (MZ-6) - a new compound with alpha-methylene-gamma-lactone motif - on two breast cancer cell lines. Chem Biol Drug Des 2012;79:112-20.
198. Wyrebska A, Szymanski J, Gach K, Piekielna J, Koszuk J, Janecki T, et al. Apoptosis-mediated cytotoxic effects of parthenolide and the new synthetic analog MZ-6 on two breast cancer cell lines. Mol Biol Rep 2013;40:1655-63.
199. Zhang D, Qiu L, Jin X, Guo Z, Guo C. Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. Mol Cancer Res 2009;7:1139-49.
200. Zhao LJ, Xu YH, Li Y. Effect of parthenolide on proliferation and apoptosis in gastric cancer cell line SGC7901. J Dig Dis 2009;10:172-80.
201. Zunino SJ, Storms DH, Ducore JM. Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11). Int J Oncol 2010;37:1307-13.
202. Hou L, Xu B, Guo W, Ran FX, Liu JT, Yuan X, et al. Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-kappaB pathway in HT-29 cells. J Cancer Res Clin Oncol 2012 Feb 8. [Epub ahead of print].
203. Khan M, Zheng B, Yi F, Rasul A, Gu Z, Li T, et al. Pseudolaric Acid B induces caspase-dependent and caspase-independent apoptosis in u87 glioblastoma cells. Evid Based Complement Alternat Med 2012;2012:957568.
204. Ma G, Chong L, Li XC, Khan IA, Walker LA, Khan SI. Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B. J Cancer Res Clin Oncol 2010;136:1333-40.
205. Meng AG, Jiang LL. Induction of G2/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway. Acta Pharmacol Sin 2009;30:442-50.
206. Meng AG, Jiang LL. Pseudolaric acid B-induced apoptosis through p53-dependent pathway in human gastric carcinoma cells. J Asian Nat Prod Res 2009;11:142-52.
207. Qi M, Yao G, Fan S, Cheng W, Tashiro S, Onodera S, et al. Pseudolaric acidBinduces mitotic catastrophe followed by apoptotic cell death in murine fibrosarcoma L929 cells. Eur J Pharmacol 2012;683:16-26.
208. Sarkar T, Nguyen TL, Su ZW, Hao J, Bai R, Gussio R, et al. Interaction of pseudolaric acid B with the colchicine site of tubulin. Biochem Pharmacol 2012;84:444-50.
209. Tong J, Yin S, Dong Y, Guo X, Fan L, Ye M, et al. Pseudolaric acid B induces caspase-dependent apoptosis and autophagic cell death in prostate cancer cells. Phytother Res 2012;27:885-91.
210. Yu JH, Cui Q, Jiang YY, Yang W, Tashiro S, Onodera S, et al. Pseudolaric acid B induces apoptosis, senescence, and mitotic arrest in human breast cancer MCF-7. Acta Pharmacol Sin 2007;28:1975-83.
211. Bu HQ, Luo J, Chen H, Zhang JH, Li HH, Guo HC, et al. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. Int J Oncol 2012;41:949-58.
212. Chen G, Wang K, Yang BY, Tang B, Chen JX, Hua ZC. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol 2012;40:139-47.
213. Chen JH, Wang SB, Li EM, Chen LM, Yuan SJ, Wang RL, et al. [Inhibitory effect of Oridonin injection on heterotransplanted gastric adenocarcinoma in nude mice and its mechanism]. Zhonghua Zhong Liu Za Zhi 2008;30:89-92.
214. Cheng Y, Qiu F, Ikejima T. Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells. Autophagy 2009;5:430-1.
215. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S, Ikejima T. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 2009;490:70-5.
216. Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 2010;10:610.
217. Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther 2012;13:1244-54.
218. Harris ES, Cao S, Schoville SD, Dong C, Wang W, Jian Z, et al. Selection for high oridonin yield in the Chinese medicinal plant Isodon (Lamiaceae) using a combined phylogenetics and population genetics approach. PLoS ONE 2012;7:e50753.
219. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 2008;107:370-9.
220. Kwan HY, Yang Z, Fong WF, Hu YM, Yu ZL, Hsiao WL. The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells. J Gastroenterol 2013;48:182-92.
221. Li CY, Wang EQ, Cheng Y, Bao JK. Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 2011;43:701-4.
222. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces human epidermoid carcinoma A431 cell apoptosis through tyrosine kinase and mitochondrial pathway. J Asian Nat Prod Res 2008;10:77-87.
223. Li X, Wang J, Ye Z, Li JC. Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci 2012;8:901-12.
224. Liu Z, Ouyang L, Peng H, Zhang WZ. Oridonin: targeting programmed cell death pathways as an anti-tumour agent. Cell Prolif 2012;45:499-507.
225. Lou H, Gao L, Wei X, Zhang Z, Zheng D, Zhang D, et al. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloids Surf B Biointerfaces 2011;87:319-25.
226. Qi X, Zhang D, Xu X, Feng F, Ren G, Chu Q, et al. Oridonin nano-suspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int J Nanomedicine 2012;7:1793-804.
227. Sun KW, Ma YY, Guan TP, Xia YJ, Shao CM, Chen LG, et al. Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J Gastroenterol 2012;18:7166-74.
228. Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen M, et al. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am J Chin Med 2013;41:177-96.
229. Benes P, Alexova P, Knopfova L, Spanova A, Smarda J. Redox state alters anti-cancer effects of wedelolactone. Environ Mol Mutagen 2012;53:515-24.
230. Benes P, Knopfova L, Trcka F, Nemajerova A, Pinheiro D, Soucek K, et al. Inhibition of topoisomerase IIalpha: novel function of wedelolactone. Cancer Lett 2011;303:29-38.
231. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer 2011;10:106.
232. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 2011;32:1013-24.
233. Hammadi A, Billard C, Faussat AM, Kolb JP. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation. Nitric Oxide 2008;19:138-45.
234. Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ 2004;11:123-30.
235. Lim S, Jang HJ, Park EH, Kim JK, Kim JM, Kim EK, et al. Wedelolactone inhibits adipogenesis through the ERK pathway in human adipose tissue-derived mesenchymal stem cells. J Cell Biochem 2012;113:3436-45.
236. Tanabe K, Nishimura K, Dohi S, Kozawa O. Mechanisms of interleukin-1beta-induced GDNF release from rat glioma cells. Brain Res 2009;1274:11-20.
237. Tsai CH, Lin FM, Yang YC, Lee MT, Cha TL, Wu GJ, et al. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res 2009;15:5435-44.
238. Chao DC, Lin LJ, Hsiang CY, Li CC, Lo HY, Liang JA, et al. Evodiamine inhibits 12-O-tetradecanoylphorbol-13-acetate-induced activator protein 1 transactivation and cell transformation in human hepatocytes. Phytother Res 2011;25:1018-23.
239. Chen MC, Yu CH, Wang SW, Pu HF, Kan SF, Lin LC, et al. Antiproliferative effects of evodiamine on human thyroid cancer cell line ARO. J Cell Biochem 2010;110:1495-503.
240. Jiang J, Hu C. Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 2009;14:1852-9.
241. Pan X, Hartley JM, Hartley JA, White KN, Wang Z, Bligh SW. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine 2012;19:618-24.
242. Rasul A, Yu B, Zhong L, Khan M, Yang H, Ma T. Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy. Oncol Rep 2012;27:1481-7.
243. Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q, et al. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells. Cancer Lett 2013;328:243-51.
244. Zhang C, Fan X, Xu X, Yang X,Wang X, Liang HP. Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells. Anticancer Drugs 2010;21:766-76.